# Dizal Pharmaceutical

Source: https://onco.cc/companies/dizal/  
OnCo record `dizal` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia.

## Summary

Dizal Pharmaceutical, based in Shanghai and listed in Shanghai, designs small-molecule drugs for cancer and immune disease. Its oncology pipeline centres on sunvozertinib, an EGFR inhibitor designed for exon 20 insertion mutations in non-small-cell lung cancer, and DZD8586, an oral inhibitor of LYN and BTK that crosses the blood-brain barrier and is being compared with investigator's choice therapy in relapsed or refractory chronic lymphocytic leukaemia. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Dizal Pharmaceuticals; Dizal (Jiangsu) Pharmaceutical Co., Ltd.; 迪哲医药
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.dizalpharma.com/

## Sources

- Official website: https://www.dizalpharma.com/
- ClinicalTrials.gov: trials led by Dizal: https://clinicaltrials.gov/search?lead=Dizal

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [DZD8586](https://onco.cc/drugs/dzd8586/), [Golidocitinib](https://onco.cc/drugs/golidocitinib/), [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)
- trials: [A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07328217/), [A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)](https://onco.cc/trials/nct07234162/), [A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins](https://onco.cc/trials/nct07182682/), [A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)](https://onco.cc/trials/nct06295432/), [A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)](https://onco.cc/trials/nct07154264/), [A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)](https://onco.cc/trials/tai-shan6/), [A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)](https://onco.cc/trials/nct05668988/), [Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)](https://onco.cc/trials/nct03974022/), [Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)](https://onco.cc/trials/nct07496229/), [DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)](https://onco.cc/trials/nct07070440/), [DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)](https://onco.cc/trials/nct07059650/), [DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)](https://onco.cc/trials/nct06539182/), [DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)](https://onco.cc/trials/nct06276283/), [Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06198907/), [Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC](https://onco.cc/trials/nct07110103/), [Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC](https://onco.cc/trials/nct06864624/), [Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)](https://onco.cc/trials/nct07079475/), [Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)](https://onco.cc/trials/nct05712902/)

---
JSON: https://onco.cc/api/v1/entities/dizal.json